GILD

SEC source: 0001213307-26-000003 · wk-form4_1777926175.xml · nonDerivative · entry 1

WELTERS ANTHONY · CIK 0001213307 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,894

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001415548-26-000003 · wk-form4_1777926298.xml · derivative · entry 2

Rodriguez Javier · CIK 0001415548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0001415548-26-000003 · wk-form4_1777926298.xml · nonDerivative · entry 1

Rodriguez Javier · CIK 0001415548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,364

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001527726-26-000002 · wk-form4_1777926054.xml · derivative · entry 3

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0001527726-26-000002 · wk-form4_1777926054.xml · nonDerivative · entry 2

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,015

SEC source: 0001527726-26-000002 · wk-form4_1777926054.xml · nonDerivative · entry 1

MANWANI HARISH · CIK 0001527726 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,239

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001629885-26-000002 · wk-form4_1777925958.xml · derivative · entry 2

Kramer Kelly A. · CIK 0001629885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F3 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0001629885-26-000002 · wk-form4_1777925958.xml · derivative · entry 1

Kramer Kelly A. · CIK 0001629885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,256

Underlying: Common Stock · 1,146 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: 100% of the restricted stock units vested immediately upon the grant date of April 30, 2026.

F2 · derivative.expiration_date: 100% of the restricted stock units vested immediately upon the grant date of April 30, 2026.

SEC source: 0001638709-26-000002 · wk-form4_1777926706.xml · derivative · entry 2

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,884

Underlying: Common Stock · 4,884 shares

Expires 2036-04-30

F2 · derivative.exercise_date: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

SEC source: 0001638709-26-000002 · wk-form4_1777926706.xml · nonDerivative · entry 1

Horning Sandra · CIK 0001638709 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,293

F1 · security: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

SEC source: 0001638643-26-000020 · wk-form4_1777499620.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 632,567

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F3 · price: Sale prices for the transactions reported range from $129.42 to $130.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000020 · wk-form4_1777499620.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 635,617

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F2 · price: Sale prices for the transactions reported range from $128.41 to $129.325. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000014 · wk-form4_1776379311.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 176,191

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001782135-26-000014 · wk-form4_1776379208.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,779

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001638643-26-000018 · wk-form4_1774907986.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 642,567

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F2 · price: Sale prices for the transactions reported range from $136.51 to $137.22. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001310204-26-000012 · wk-form4_1773785637.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 179,191

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

SEC source: 0001782135-26-000012 · wk-form4_1773788187.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 131,779

F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · derivative · entry 5

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,880

Underlying: Common Stock · 35,880 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · derivative · entry 4

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,647

Underlying: Common Stock · 9,590 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · derivative · entry 3

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,057

Underlying: Common Stock · 6,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · nonDerivative · entry 2

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,191

SEC source: 0001310204-26-000010 · wk-form4_1773348337.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 185,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · derivative · entry 5

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,755

Underlying: Common Stock · 122,755 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · derivative · entry 4

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,859

Underlying: Common Stock · 32,815 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · derivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,044

Underlying: Common Stock · 20,026 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 652,567

SEC source: 0001638643-26-000014 · wk-form4_1773347089.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662,334

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · derivative · entry 5

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,475

Underlying: Common Stock · 31,475 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · derivative · entry 4

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,461

Underlying: Common Stock · 8,415 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · derivative · entry 3

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,046

Underlying: Common Stock · 2,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · nonDerivative · entry 2

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,982

SEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · nonDerivative · entry 1

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · derivative · entry 5

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,880

Underlying: Common Stock · 35,880 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · derivative · entry 4

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,647

Underlying: Common Stock · 9,590 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · derivative · entry 3

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,057

Underlying: Common Stock · 6,617 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · nonDerivative · entry 2

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,779

SEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · nonDerivative · entry 1

Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001927648-26-000002 · wk-form4_1773347863.xml · derivative · entry 2

Burkhart Erin · CIK 0001927648 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,455

Underlying: Common Stock · 5,455 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0001927648-26-000002 · wk-form4_1773347863.xml · derivative · entry 1

Burkhart Erin · CIK 0001927648 · SVP, Controllership

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,245

Underlying: Common Stock · 2,355 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · derivative · entry 5

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,885

Underlying: Common Stock · 18,885 shares

Expires 2036-03-10

F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · derivative · entry 4

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,586

Underlying: Common Stock · 5,050 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · derivative · entry 3

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,536

Underlying: Common Stock · 1,246 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

SEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · nonDerivative · entry 2

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,054

SEC source: 0002110603-26-000006 · wk-form4_1773347997.xml · nonDerivative · entry 1

Cain Wettan Keeley M · CIK 0002110603 · EVP Gen Counsel, Legal & Comp

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,660

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

SEC source: 0001310204-26-000008 · wk-form4_1772488649.xml · nonDerivative · entry 1

Dickinson Andrew D · CIK 0001310204 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,869

F1 · acquired: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 4

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 642,308

F2 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

SEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 3

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 642,408

F2 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F4 · price: Sale prices for the transactions reported range from $144.66 to $145.65. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 2

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 648,827

F2 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

F3 · price: Sale prices for the transactions reported range from $143.63 to $144.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

SEC source: 0001638643-26-000012 · wk-form4_1772487977.xml · nonDerivative · entry 1

O'Day Daniel Patrick · CIK 0001638643 · Director · Chairman & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 652,308

F1 · acquired: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.

SEC source: 0001739515-26-000004 · wk-form4_1772488286.xml · nonDerivative · entry 1

Berger Dietmar · CIK 0001739515 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,912

F1 · kind: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors.